Retatrutide (GLP-3) Made Me Hungrier… But I Lost Weight
In this video, MD‑PhD scientist and metabolic health communicator Nick Norwitz documents a three‑week self‑experiment with the GLP‑3 weight‑loss drug retatrutide (RETA). He reports that during the trial his resting heart rate and body temperature rose quickly, he experienced an increase in hunger, yet he still lost weight. Norwitz explains that retatrutide simultaneously activates three hormonal pathways: GLP‑1 (which can suppress appetite, as seen with drugs like Ozempic and Wegovy), GIP (which influences how nutrients are partitioned), and glucagon (which raises metabolic rate). He suggests that individual variability in how these pathways are affected may explain why some users lose appetite while others become hungrier. Concluding that his primary effect was a metabolic‑rate boost that drove hunger, he promises follow‑up content, invites viewer questions, and encourages subscription for deeper health‑science discussion.
